No­vo Nordisk in­creas­es 2023 sales, prof­it out­look as semaglu­tide sales boom

No­vo Nordisk an­nounced sub­stan­tial first-quar­ter sales growth for two of its three semaglu­tide prod­ucts, Ozem­pic and We­govy, and is rais­ing its full-year rev­enue and prof­it out­look based on their strength.

First-quar­ter sales were up 25%, the Dan­ish drug­mak­er an­nounced Thurs­day, com­pared with 42.03 bil­lion Dan­ish kro­ner, or rough­ly $6.2 bil­lion, a year ago. Quar­ter­ly op­er­at­ing prof­it was up 28%, the com­pa­ny said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.